ADMA Biologics, Inc. (NASDAQ:ADMA) Shares Sold by Martingale Asset Management L P

Martingale Asset Management L P trimmed its stake in ADMA Biologics, Inc. (NASDAQ:ADMA) by 12.2% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 50,346 shares of the biotechnology company’s stock after selling 6,981 shares during the quarter. Martingale Asset Management L P’s holdings in ADMA Biologics were worth $1,006,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently bought and sold shares of ADMA. Quest Partners LLC purchased a new position in shares of ADMA Biologics in the 2nd quarter worth about $29,000. Hollencrest Capital Management purchased a new position in ADMA Biologics in the third quarter valued at approximately $30,000. Larson Financial Group LLC acquired a new position in ADMA Biologics during the third quarter valued at approximately $31,000. Harvest Fund Management Co. Ltd purchased a new stake in ADMA Biologics during the third quarter worth approximately $62,000. Finally, CWM LLC increased its position in shares of ADMA Biologics by 114.2% in the second quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock worth $92,000 after acquiring an additional 4,367 shares in the last quarter. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analysts Set New Price Targets

ADMA has been the topic of several recent research reports. HC Wainwright lifted their target price on shares of ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James raised their target price on ADMA Biologics from $18.00 to $25.00 and gave the company a “strong-buy” rating in a report on Friday, November 8th.

Insider Activity at ADMA Biologics

In related news, Director Lawrence P. Guiheen sold 9,000 shares of the business’s stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total value of $166,230.00. Following the completion of the sale, the director now directly owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The trade was a 5.52 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Brad L. Tade sold 15,000 shares of the stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the transaction, the chief financial officer now directly owns 199,433 shares in the company, valued at approximately $4,218,007.95. This represents a 7.00 % decrease in their position. The disclosure for this sale can be found here. 3.70% of the stock is currently owned by corporate insiders.

ADMA Biologics Stock Down 2.1 %

Shares of ADMA Biologics stock opened at $19.69 on Tuesday. ADMA Biologics, Inc. has a 1-year low of $3.60 and a 1-year high of $23.64. The company has a market capitalization of $4.65 billion, a PE ratio of 70.32 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a current ratio of 7.09 and a quick ratio of 3.26. The business has a 50-day moving average of $19.07 and a 200-day moving average of $15.47.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. ADMA Biologics had a return on equity of 53.20% and a net margin of 17.80%. The firm had revenue of $119.84 million during the quarter, compared to analyst estimates of $107.25 million. During the same quarter last year, the firm earned $0.01 EPS. As a group, equities analysts forecast that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.